The Pulmonary Arterial Hypertension (PAH) market size is projected to reach a CAGR of 5.2% from 2022 to 2028.
Pulmonary Arterial Hypertension (PAH) is a life-threatening condition that is progressive condition wherein the blood at higher blood pressure goes from heart to the lungs. This is caused due to the blockage and narrowing of arteries at the lungs. Thus, heart has to pump the blood with higher pressure toward the lungs.
Expansion of key players along with the surged incidents of pulmonary arterial hypertension and lifestyle disorders are some of the factors that have supported long-term expansion for Pulmonary Arterial Hypertension (PAH) Market.
COVID-19 had a marginal effect on the market, as the supply chains were disrupted along with the effects of pandemic on the financial activities.
North America is the most rapidly growing market and offers a huge opportunity for the industry, whose growth is driven by the increased awareness and the raised health concerns amongst people and the presence of key players in the region.
Insights are provided for each region and major countries within the regions
|
Report Feature |
Descriptions |
|---|---|
|
Growth Rate |
CAGR of 5.2% during the forecasting period, 2022-2028 |
|
Historical Data |
2019-2020 |
|
Forecast Years |
2022-2028 |
|
Base Year |
2021 |
|
Units Considered |
Revenue in USD billion and CAGR from 2022 to 2028 |
|
Report Segmentation |
drug class, type, route of administration and region. |
|
Report Attribute |
Market Revenue Sizing (Global, Regional and Country Level) Company Share Analysis, Market Dynamics, Company Profiling |
|
Regional Level Scope |
North America, Europe, Asia-Pacific, South America, and Middle East and Africa |
|
Country Level Scope |
U.S., Japan, Germany, U.K., China, India, Brazil, UAE, South Africa (50+ Countries Across the Globe) |
|
Companies Profiled |
United Therapeutics Corporation; Bayer; Gilead Sciences, Inc.; Johnson & Johnson; Viatris Inc.; GlaxoSmithKline; Sandoz Inc. (Novartis); Lupin Pharmaceuticals, Inc.; Sun Pharmaceutical Industries, Inc.; Teva Pharmaceuticals Inc. |
|
Available Customization |
In addition to the market data for Pulmonary Arterial Hypertension (PAH) Market, Delvens offers client-centric report and customized according to the company’s specific demand and requirement. |
Pulmonary Arterial Hypertension (PAH) Market is segmented into drug class, type, route of administration and region.
.png)
.png)
.png)
.png)
.png)
.png)